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Summary 
Setting: The value of microbiologic criteria in diagnosing nontuberculous mycobacteria 
pulmonary disease (NTM-PD) and monitoring its epidemiology is unknown.  
Objectives: To correlate the rate of NTM-PD based on microbiologic criteria (American 
Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] or stricter 
microbiologic criteria) with the full ATS/IDSA criteria, and assess the positive predictive 
value (PPV) of different microbiologic criteria in predicting NTM-PD. To evaluate the 
clinical relevance of different NTM species. Design: Retrospective study of all patients with 
pulmonary NTM isolates in Croatia during an eight-year period. NTM species were divided 
into low, intermediate, and high clinical relevance groups for additional analyses. Results: 
Good correlation between both microbiologic and full ATS/IDSA criteria was shown. PPV of 
stricter and ATS/IDSA microbiologic criteria was 93.3% and 59.8%, respectively. Usefulness 
of microbiologic criteria varied between groups. ATS/IDSA microbiologic criteria had a PPV 
of 89.8% in the high relevance group. In the intermediate relevance group, the PPV of stricter 
and ATS/IDSA microbiologic criteria were 94.3% and 63.4%, respectively. Conclusions: 
Microbiologic criteria are useful in detecting NTM-PD, allowing laboratory based monitoring. 
Stricter criteria should be used for species of low clinical relevance, and less stringent criteria 
for species of high relevance in the local setting. 
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INTRODUCTION 
Nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms with variable 
potential to cause disease.
1
 Interest in NTM continuously grows due to reported increase in 
isolation frequency 
1-5
, particularly in countries where the incidence of tuberculosis (TB) is 
declining.
1,6
 Diagnosis of NTM pulmonary diseases (NTM-PD) is difficult. Currently, the 
criteria proposed by the American Thoracic Society (ATS) and Infectious Diseases Society of 
America (IDSA) provide the best guide for the diagnosis. (Table 1).
1
 Patients should have a 
combination of clinical, radiological and microbiological characteristics, together with the 
exclusion of alternative diagnoses. This approach, similar to the one recently proposed for the 
diagnosis and management of chronic pulmonary aspergillosis 
7
, a disease that can follow or 
occur contemporaneously with NTM-PD, further emphasizes the complexity of the disease. 
The epidemiology of NTM-PD is challenging to determine because reporting is not 
mandatory in most countries and identification of definite disease is difficoult.
1,8
 Data from 
intermediate TB burden countries such as Croatia 
9,10
 are especially scarce. Laboratory-based 
surveillance may be the most cost-effective method for estimating the NTM disease burden 
over time.
11,12
 Our previous study, using only ATS/IDSA microbiologic criteria or stricter 
microbiologic criteria estimated the incidence of NTM-PD in Croatia to 0.61 and 0.23 per 100 
000 population, respectively.
13
 The disease proved most prevalent in older populations with 
three-fold increase in NTM-PD incidence in persons older than 50 years.
13
 In the current 
study, we sought to correlate microbiologic criteria to full ATS/IDSA diagnostic criteria and 
validate the use of microbiologic criteria in the estimation of NTM-PD incidence/prevalence.  
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METHODS 
Study design and data collection 
We conducted a retrospective cohort study on all Croatian residents with NTM isolated from 
respiratory samples in the period from January 1
st
 2006 to December 31
st
 2013. Since all 
NTM isolates are sent to the National Reference Mycobacteria Laboratory (NRML) at 
Croatian Institute of Public Health (CIPH) for species identification, we obtained patient 
information from the NRML archive. For each patient, we recorded age, zip code, specimen 
collection date, as well as source and the NTM species isolated. Samples obtained by gastric 
lavage were excluded from further analysis. In case of multiple isolates of one or more 
species, only one isolate per species per individual was taken into account when calculating 
NTM isolation rate. Using the zip code, patients were grouped into two larger areas according 
to the proximity of the sea, coastal and continental regions of Croatia.
14
 The Croatian 
population data, including population by region, age and sex, were obtained from the 
statistical office of the European Union.
15
 The study was approved by the Ethics Committee 
of the CIPH (file number 001-487/1-10). 
 
Identification of NTM and NTM pulmonary disease case definition  
 
All NTM species were identified by molecular methods (GenoType® CM/AS; Hain 
Lifescience GmbH) supplemented with phenotypic methods, using previously published 
guidelines.
16
 NTM unidentifiable to species level were sent to the Supranational Reference 
Laboratory (Forschungszentrum Borstel, Germany or Emerging Pathogens Institute, Milan, 
Italy) for further identification by 16S rDNA gene sequencing.  
We used the ATS/IDSA microbiologic criteria (Table 1) 
1
 and stricter microbiologic criteria 
(more than two positive sputum samples or one positive BAL/ brush and one or more positive 
sputum samples) 
13
 to establish a laboratory-based diagnosis of NTM-PD. Furthermore, 
clinical and radiological data were gathered in order to evaluate whether patients had 
symptoms and radiological findings compatible with the diagnosis of NTM-PD according to 
the full ATS/IDSA criteria.
1
 In case of concurrent active respiratory disease more likely to be 
the cause of symptoms (i.e. active tuberculosis, concomitant isolation of significant 
respiratory pathogens such as Streptococcus pneumoniae and resolution of 
symptoms/radiological findings after the appropriate treatment), NTM were ruled out as a 
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cause of the disease. For calculating disease incidence, we took into account the first time that 
NTM-PD criteria were met. For individuals meeting these criteria, patients with NTM isolated 
in 2005 were excluded from disease incidence calculation.  
 
Clinical relevance of NTM species and criteria correlations 
 
For NTM species with more than 10 isolates with available complete patient’s medical 
records, clinical relevance was evaluated based on the percentage of patients meeting the full 
ATS/IDSA criteria. Based on that percentage, NTM species were divided into three groups: 
„low relevance“ (<25% of isolates meeting full criteria), „intermediate relevance“ (25-70% of 
isolates meeting full criteria) and „high relevance“ (>70% meeting full criteria). NTM-PD 
diagnosis based on ATS/IDSA or stricter microbiologic criteria were correlated with the rate 
of diagnosis based on full ATS criteria. Correlation of the criteria was also calculated for the 
three groups. 
 
Data analysis  
Microsoft Excel (Microsoft, Redmond, WA, USA) was used to calculate frequencies, 
percentages, median age, and crude and standardized rates. The χ2 and χ2 test for trend, 
correlation coefficients as well as rate comparisons were done using MedCalc (MedCalc 
Software, Ostend, Belgium)  
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RESULTS 
During the study period, the NRML identified a total of 2105 pulmonary NTM isolates from 
1841 patients. Average annual NTM isolation incidence amounted to 5.21 per 100 000 
population. The most frequently isolated NTM species, percentage of patients meeting at least 
one microbiologic criterion, and percentage of patients with available medical records per 
species are shown in Table 2.  
The species distribution differed between coastal and continental Croatia: M. gordonae (OR 
1.62, 95% confidence interval (CI) 1.25 to 1.97; p<0.0001), M. terrae (OR 2.72, 95% CI 1.86 
to 6.51; p<0.0001,) and M. chelonae (OR 2.11, 95% CI 1.10 to 4.23; p=0.022) were 
significantly more frequently isolated in continental Croatia, whereas M. avium (OR 0.35, 95% 
CI 0.19 to 0.58; p<0.0001), M. kansasii (OR 0.45, 95% CI 0.19 to 0.96; p=0.033), and M. 
xenopi (OR 0.27, 95% CI 0.22 to 0.38; p<0.0001) were more frequent in the coastal region. 
Of 1841 patients with NTM isolates, 58.6% were male (median age 65), and 41.6% female 
(median age 66 years).  
 
NTM pulmonary disease and clinical relevance of NTM species 
 
Out of 1841 patients, 370 (20.1%) and 111 (6%) met ATS/IDSA and stricter microbiologic 
criteria, respectively. The demographic characteristics of these patients are shown in Table 3. 
Medical records were available for 411 (22.34%) patients. Out of 411 patients, 278 (67.6%) 
had no disease, while 105 (25.6%) had NTM-PD according to the full ATS/IDSA criteria. For 
28 (6.8%) patients, the available data were highly suggestive of NTM-PD, but the disease 
couldn’t bee definitively confirmed due to not fulfilling the microbiologic part of the 
ATS/IDSA criteria (usually because of only single sputum culture taken). Thus, although 
those patients had a probable NTM-PD, they were excluded from further analyses.  
Clinical characteristics of patients who met full ATS/IDSA NTM-PD criteria and those who 
did not are shown in Table 4. The two groups were similar regarding age and medical 
comorbidities, but some differences have been found (Table 4). Among patients with NTM-
PD, females were significantly older compared to males (70 vs. 63 yr; t-test p=0.015), less 
likely to present with cavitary disease (OR 0.39, CI 0.16 to 0.98; p=0.04), more likely to have 
bronchiectasies (OR 3.21, CI 1.36 to 7.6; p=0.007), and more likely to be a nonsmoker (OR 
19.63, CI 7.12 to 54.09; p<0.0001). 
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Estimated clinical relevance of isolates according to the percentage of patients meeting full 
ATS/IDSA criteria is shown in Figure 1. On the basis of this percentage, we classified NTM 
species into three groups: „low relevance“- M. terrae, M. fortuitum, M. gordonae and M. 
chelonae; „intermediate relevance“- M. kansasii, M. xenopi, and M. abscessus complex 
(MABSC); „high relevance“– M. avium complex (MAC). 
 
Criteria correlation and NTM pulmonary disease incidence 
 
The phi coefficient for correlation between different microbiologic criteria and full 
ATS/IDSA criteria is shown in Table 5. Positive predictive values (PPV) of ATS/IDSA 
microbiologic criteria and stricter microbiologic criteria were 59.3% and 93.2%, respectively. 
While ATS/IDSA microbiologic criteria had a PPV of 89.8% in the high relevance group, in 
the intermediate relevance group, the PPV of stricter microbiologic criteria was considerably 
higher in comparison to ATS/IDSA microbiologic criteria (94.3 vs. 63.4%).  
Based on ATS/IDSA and stricter microbiologic criteria, we estimated the average annual 
NTM-PD incidence at 1.07/100 000 and 0.32/100 000, respectively (Table 3). Incidence was 
higher in the coastal compared to the continental region, with no significant increase of 
incidence over the studied period. On the basis of patients with available medical records, the 
estimated average annual incidence of the NTM-PD was 0.29/100 000.  
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DISCUSSION 
 
This population-based study addresses the usefulness of microbiologic laboratory data in the 
monitoring of NTM-PD prevalence, and the PPV of microbiologic criteria in the detection of 
NTM-PD. The retrospective design and reliance on complex ATS/IDSA criteria for 
establishing NTM-PD represent potential limitations in the interpretation of the study results. 
Still, these criteria are currently the best available tool and the most widely used method for 
diagnosing NTM-PD.  
 
Criteria correlation  
Overall, we have shown moderate to good correlation between both microbiologic criteria, 
and full ATS/IDSA criteria. Still, PPV of stricter microbiologic criteria was considerably 
higher when compared to ATS/IDSA microbiologic criteria (93.3% vs. 59.8%). Furthermore, 
different microbiologic criteria perform differently in predicting NTM-PD for various NTM 
species. Stricter criteria, when compared to ATS/IDSA microbiologic criteria, show 
significantly higher PPV for NTM-PD caused by species of intermediate clinical relevance. 
On the other hand, the ATS/IDSA microbiologic criteria have very high PPV for detecting 
NTM-PD caused by NTM species of high clinical relevance, and the usage of stricter criteria 
in this group likely underestimates the disease incidence. Our overall result appears to be in 
disagreement with Winthrop et al. who showed the PPV of 86% for ATS/IDSA microbiologic 
criteria in predicting NTM-PD.
12
 The proportion of patients with NTM-PD caused by MAC in 
Winthrop’s study was significantly higher (88% vs. 43% in the current study). The 
discrepancy in MAC incidence could explain the significant difference between PPV of 
ATS/IDSA microbiologic criteria in the two studies. The PPV for NTM species of high 
clinical relevance (89.8%), which in our setting comprises members of MAC, is in agreement 
with their finding. Several studies showed higher PPV (70-90%) of ATS/IDSA microbiologic 
criteria in predicting NTM-PD, but the studied cohorts mostly comprised patients with NTM 
isolates of significant or, at least, intermediate clinical relevance (MAC, M. xenopi, 
MABSC).
4,17,18
 Thus, to prevent unwarranted diagnoses and treatment of NTM disease, as 
well as unnecessary diagnostic delay, it could be helpful to use separate, more stringent 
criteria for species of low relevance, and less stringent criteria for species considered to be of 
high clinical relevance in the local setting. This aspect should be covered in the upcoming 
diagnostic criteria. However, such stratified system further complicates the diagnostic criteria, 
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and requires users’ awareness of species distribution and clinical relevance in their local 
area.
19
 
 
NTM species distribution differs by region 
Most species isolated in continental region were of low clinical relevance. M. gordonae was 
the most commonly isolated NTM species, with a peak isolation frequency in 2009 (data not 
shown) that can be explained by contamination of tap water with M. gordonae in one 
hospital.
20
 In contrast, clinically relevant NTM species were more common in the coastal 
region. Some of the factors that might promote these regional differences include the climate, 
the rate of urbanization and different rates of TB incidence. The more urbanized coastal 
region 
14
 has a more humid, warmer climate and relies on larger municipal water supplies. 
Furthermore, the incidence of TB was lower in the coastal region than in the continental 
region (21.2 vs. 30.1/100 000 in 2006).
9
 The observation that species distribution differs by 
region mirrors findings from the recent NTM-NET study, which also showed major 
differences between and within countries.
21
 The association between difference in species 
distribution and disease prevalence between coastal and continental regions has not been 
previously shown in other settings. A recent study from USA showed that regional 
environmental factors related to soil and differences in daily evapotranspiration levels are 
associated with NTM-PD, but that both the host susceptibility and environmental factors 
should be considered in explaining disease development.
22
 
 
 
Clinical relevance differs by NTM species 
Medical records were available for a total of 22.3% patients, but the percentage of patients 
with evaluated records reached over 60% in case of NTM species of presumably higher 
clinical interest (i.e. MAC, M. xenopi). Also, we managed to evaluate a significant number of 
medical records from patients with NTM species considered to be of low clinical relevance in 
order to have comparable groups (Table 2).   
Although M. xenopi was the primary cause of NTM-PD, only around 25% of patients with M. 
xenopi isolates had the disease according to the full ATS/IDSA criteria. MAC was found to be 
clinically the most relevant species, while M. gordonae, M. terrae, M. chelonae and M. 
fortuitum showed very low or no clinical significance. M. kansasii and MABSC were 
infrequently isolated, and around 60% and 42% of patients with these isolates met the disease 
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criteria, respectively. These findings differ from observations in the Netherlands where 
clinical relevance for M. kansasii and M. xenopi exceeded that of MAC.
3,23
 Also, in a study 
from Korea, MABSC was among the most frequently isolated NTM species with considerably 
higher clinical relevance compared to our results.
24
 The exact reason for such apparent 
regional differences remains unknown. However, the limited significance of M. kansasii in 
our study may result from its infrequent isolation and the fact that many patients had a 
concomitant disease (i.e. active tuberculosis) which was a more plausible cause of the 
symptoms. In addition, we haven’t performed sub-typing, and it has been shown that some 
subtypes of M. kansasii are typically environmental microorganisms of little or no clinical 
significance.
25
  
 
 
Incidence and prevalence of NTM-PD in Croatia 
Based on full ATS/IDSA criteria, our calculated NTM-PD annual incidence of 0.29/100 000 
mirrors the incidence previously calculated using stricter microbiologic criteria (0.23/100 
000).
13
 Use of ATS/IDSA microbiologic criteria (0.61/100 000) overestimated disease 
incidence. This overestimation results from a relatively high proportion of clinically 
insignificant NTM species (such as M. gordonae, M. terrae and M. fortuitum) meeting the 
ATS/IDSA microbiologic criteria. Both incidence and prevalence of NTM-PD are higher in 
coastal than continental region which might reflect the NTM species distribution in these 
regions. NTM-PD incidence in Croatia is low compared to TB incidence as well as to NTM-
PD incidence in North-Western Europe 
4,26-28
, North America 
11,17,22,29,30
, Australia 
31
 and 
Japan.
32
 Similar disease incidence was recorded in Greece 
33,34
 and Sao Paulo region, Brasil.
35
 
Generally, the prevalence of NTM-PD in Europe is substantially lower than in North America, 
Australia and Japan.
5
 The exact reasons for such apparent differences remain to be elucidated 
in future studies.  
 
 
CONCLUSION 
We have shown that microbiologic criteria are useful in detecting NTM-PD, but that more 
stringent criteria should be used for species of low relevance, and less stringent criteria for 
species considered to be of high clinical relevance in the local setting. Microbiologic criteria 
used to define NTM-PD can be helpful to monitor the epidemiology of NTM-PD in settings 
11 
 
where notification of cases is not obligatory. Still, usage of ATS/IDSA microbiologic criteria 
alone, in our setting, overestimates the disease prevalence. In our setting, stricter 
microbiologic criteria should be used in a laboratory based surveillance of NTM-PD.  
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Table 1 
ATS/IDSA criteria for diagnosing nontuberculous mycobacterial (NTM) pulmonary disease 
1
 
Clinical criteria Respiratory or constitutional symptoms, and 
Appropriate exclusion of other diagnoses, and 
Radiological criteria reticular, interstitial, nodular infiltrate, or cavitation on chest 
radiograph, or high-resolution computed tomography scan 
that shows multifocal bronchiectasies with multiple small 
nodules, and 
Microbiological criteria Positive culture results from at least 2 separate expectorated 
sputum samples, or 
Positive cultures from at least 1 bronchial wash or lavage*, or 
Transbronchial or other lung biopsy with mycobacterial 
histopathologic features (granulomatous inflammation or 
acid-fast bacilli ) and positive culture for NTM, or biopsy 
showing mycobacterial histopathologic features and one 
sputum sample or bronchial washing/lavage that is culture 
positive for NTM 
*applies to patients incapable of producing sputum samples 
ATS/IDSA – American Thoracic Society/Infectious Diseases Society of America 
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Table 2. Nontuberculous mycobacteria isolation frequency in Croatia according to the geographic region, sex, and microbiologic criteria 
1,13
 
  Gender Region Meeting the microbiologic criteria 
NTM Total 
M  
n (%) 
F 
n (%) 
Inland 
n (%) 
Coast 
n (%) 
Unknow
n 
n (%) 
Only 
ATS/IDSA 
n (%) 
Strict 
n (%) 
Not 
satisfied 
n (%) 
Medical 
records 
evaluate
d (%) 
M. gordonae 760 
443 
(58.3) 
317 
(41.7) 618 (81.3) 
140 
(18.4) 2 (0.3) 78 (10.3) 13 (1.7) 669 (88) 59 (7.8) 
M. xenopi 288 
190 
(66) 98 (34) 153 (53.1) 
133 
(46.2) 2 (0.7) 71 (24.6) 
33 
(11.5) 
184 
(63.9) 167(58) 
M. fortuitum 229 
141 
(61.6) 88 (38.4) 186 (81.2) 43 (18.8) 0 (0) 29 (12.7) 6 (2.6) 
194 
(84.7) 
61 
(26.6) 
M. terrae 132 
71 
(53.8) 61 (46.2) 118 (89.4) 14 (10.6) 0 (0) 8 (6.1) 2 (1.5) 
122 
(92.4) 13 (9.8) 
MAC 101 
50 
(49.5) 51 (50.5) 63 (62.4) 38 (37.6) 0 (0) 34 (33.66) 
31 
(30.7) 
36 
(35.6) 
63 
(62.4) 
M. avium 57 
28 
(49.1) 29 (50.9) 31 (54.4) 26 (45.6) 0 (0) 23 (40.35) 
16 
(28.1) 
18 
(31.6) 
38 
(66.7) 
M. 
intracellulare 41 
22 
(53.7) 19 (46.3) 29 (70.7) 12 (29.3) 0 (0) 11 (26.83) 
15 
(36.6) 
15 
(36.59) 25 (61) 
MAC-X 3 0 (0) 3 (100) 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100)  (0) 
M. chelonae 85 
49 
(57.7) 36 (42.3) 74 (87.1) 11 (12.9) 0 (0) 16 (18.8) 4 (4.7) 
65 
(76.5) 
15 
(17.7) 
MABSC 47 
26 
(55.3) 21 (44.7) 41 (87.2) 6 (12.8) 0 (0) 5 (10.6) 
10 
(21.3) 
32 
(68.1) 
12 
(25.5) 
M. kansasii 26 
15 
(57.69) 
11 
(42.31) 15 (57.69) 
10 
(38.46) 1 (3.85) 7 (26.92) 
5 
(19.23) 
14 
(53.85) 
12 
(46.2) 
Other 173 
91 
(52.6) 82 (47.4) 
138 
(79.77) 
34 
(19.65) 1 (0.58) 11 (6.36) 7 (4.05) 
155 
(89.6) 9 (5.2) 
Total 1841 
1076 
(58.4) 
765 
(41.6) 
1406 
(76.4) 
429 
(23.3) 6 (0.3) 259 (14.1) 111 (6) 
1471 
(79.9) 
411 
(22.3) 
14 
 
MAC – Mycobacterium avium complex; MABSC – M. abscessus complex; ATS/IDSA microbiologic criteria - two positive sputum samples or 
one positive bronchoalveolar lavage (BAL) or brush); Strict microbiologic criteria - more than two positive sputum samples or one positive BAL/ 
brush and one or more positive sputum samples) 
15 
 
Table 3. Demographic characteristics of patients meeting the ATS/IDSA microbiological 
criteria and strict microbiologic criteria for nontuberculous mycobacterial pulmonary disease 
in Croatia 
 
 Strict microbiologic criteria ATS/IDSA microbiologic 
criteria only 
 
Cases 
Value 
(%) 
Median 
age 
Average 
incidenc
e (per 
100.000) 
Value 
(%) 
Median 
age 
Average 
annual 
incidence 
(per 
100.000) 
Average 
populatio
n 
All cases 
111 
(100)       67        0.32 
259 
(100)  67      0.75 4 297 326 
Gender 
Female 
46 
(41.4)  67 0.26 
95 
(36.7)  66 0.53 2 226 568 
Male 
65 
(58.6)  67 0.39 
164 
(63.3)  67.5 0.99 2 070 758 
Age 
0-49 
15 
(13.5)  38 0.07 44 (17)  34 0.21 2 657 136 
50-69 51 (46)  62 0.58 
103 
(39.8)  62 1.16 1 094 909 
70+ 
45 
(40.5)  77 1.04 
110 
(42.5)  78 2.46 542 867 
50+ 
96 
(86.5)  68.5 0.73 
213 
(82.2)  70 1.60 1 637 776 
Unknow
n 0 (0)      2 (0.7)        
Geographic location             
Continen
tal 
64 
(57.7)  65.5 0.28 
173 
(66.8)  67 0.75 2 887 134 
Coastal 
47 
(42.3)  69 0.42 
85 
(32.8)  68 0.75 1 410 192 
Unknow
n 0 (0)      1 (0.4)        
ATS – American Thoracic Society; IDSA – Infectious Diseases Society of America; 
ATS/IDSA microbiologic criteria - two positive sputum samples or one positive 
bronchoalveolar lavage (BAL) or brush); Strict microbiologic criteria - more than two 
positive sputum samples or one positive BAL/ brush and one or more positive sputum 
samples) 
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Table 4. Characteristics of patients with clinically evaluable records that met full ATS/IDSA 
NTM pulmonary disease criteria 
1
 compared with patients with respiratory NTM isolates who 
did not meet criteria  
Characteristics Confirmed case 
(n=105) 
Did not meet full 
ATS/IDSA 
criteria (n=278) 
P value 
Demographics: 
Age (median, range) 66 (16-90) 66 (14-90)  
Female sex 51 (48.6%) 80 (28.8%) 0.0004 
Chest radiographic abnormalities: 
Infiltrate 
74 (70.5%) 16 (5.8%) 
<0.000
1 
Cavity 
28 (26.7%) 11 (4%) 
<0.000
1 
Pleural effusion  5 (4.8%) 30 (10.8%) 0.07 
Concurrent and predisposing conditions 
COPD  48 (45.7%) 112 (40.3%) 0.34 
Bronchiectasis  
34 (32.4%) 21 (7.6%) 
<0.000
1 
Prior tuberculosis  28 (26.7%) 49 (17.6%) 0.068 
Diabetes mellitus  15 (14.3%) 32 (11.5%) 0.46 
Below normal BMI 
37 (35.2%) 19 (6.8%) 
<0.000
1 
GERD 5 (4.8%) 15 (5.4%) 0.8 
Lung cancer*  3 (2.9%) 34 (12.2%) 0.01 
Alcohol abuse  5 (4.8%) 22 (7.9%) 0.28 
Current smoker  29 (27.6%) 73 (26.3%) 0.79 
Past smoker  29 (27.6%) 97 (34.9%) 0.18 
Nonsmoker  45 (42.9%) 93 (33.5%) 0.09 
Signs and symptoms 
Productive cough 78 (74.3%) 173 (62.2%) 0.017 
Malaise 66 (62.9%) 86 (30.9%) 
<0.000
1 
Apetite loss 37 (35.2%) 78 (28.1%) 0.17 
Fever 34 (32.4%) 93 (33.5%) 0.84 
Hemoptysis 28 (26.7%) 27 (9.7%) 
<0.000
1 
Increased sweating 10 (9.5%) 21 (7.6%) 0.53 
ATS/IDSA – American Thoracic Society/Infectious Diseases Society of America; BMI – 
body mass index; COPD – chronic obstructive pulmonary disease; GERD – gastroesophageal 
reflux disease; Tx – therapy; * active disease or surgically resected within the last year 
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Table 5. Correlation of NTM pulmonary disease diagnosed according to the different 
microbiologic and full ATS/IDSA criteria, and positive predictive value for the use of 
microbiologic criteria in establishing NTM-PD diagnosis.  
 
NTM 
species* 
Phi coefficient of 
correlation of 
ATS/IDSA 
microbiologic 
criteria with the 
whole ATS/IDSA 
criteria 
PPV for 
ATS/IDSA 
microbiologic 
criteria 
Phi coefficient of 
correlation of 
stricter 
microbiologic 
criteria with the 
whole 
ATS/IDSA 
criteria 
PPV for stricter 
microbiologic 
criteria 
All species 
0.66 
(95% CI 0.60-0.72; 
p<0.0001) 
59.3% 
(95% CI 51.7 - 
66.6) 
0.73 
(95% CI 0.68-
0.77; p<0.0001) 
93.2% 
(95%CI 84.9 - 
97.8) 
Low 
relevance 
0.28 
(95% CI 0.12-0.43; 
p=0.001) 
10.5% 
(95%CI 2.9-
25.1) 
0.6 
(95% CI 0.48-
0.7; p<0.0001) 
50% 
(95%CI 9.4-
90.6) 
Intermediate 
relevance 
0.69 
(95% CI 0.6-0.76; 
p<0.0001) 
63.4% 
(95% CI 52.0-
73.8) 
0.7 
(95%CI 0.62-
0.77; p<0.0001) 
94.3% 
(95% CI 80.6-
99.3) 
High 
relevance 
0.77 
(95% CI 0.64-0.86; 
p<0.0001) 
89.8% 
(95% CI 77.2-
96.6) 
0.57 
(95% CI 0.37-
0.72; p<0.0001) 
100% 
(95% CI 87.2-
100) 
PPV – positive predictive value; ATS – American Thoracic Society; IDSA - Infectious 
Diseases Society of America; * - „low relevance“: <25% of isolates meeting full ATS/IDSA 
criteria; „intermediate relevance“: 25-70% of isolates meeting full criteria; “high 
relevance“: >70% of isolates meeting full criteria. 
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Figure 1. Clinical relevance of nontuberculous mycobacteria isolated from respiratory 
samples according to the percentage of patients meeting the full ATS/IDSA diagnostic criteria 
1
 
 
ATS – American Thoracic Society; IDSA - Infectious Diseases Society of America; 
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